PhytoMedical Technologies, Inc. Announces Key Developmental Partner For New Cachexia Compound, Which Has Active Elements That Increase Lean Muscle Mass And Reduce Body Fat

PRINCETON, N.J.--(BUSINESS WIRE)--July 10, 2006--PhytoMedical Technologies, Inc. (OTCBB:PYTO - News; FWB:ET6) (WKN:A0B79T) announced today that it has entered into a development agreement with Ricerca BioSciences, a world class pharmaceutical development lab. “This is a historic milestone in the life of PhytoMedical,” commented Mr. Greg Wujek, President and CEO of PhytoMedical. “Partnering with a sophisticated and respected lab such as Ricerca provides us with a complete range of developmental capabilities, allowing us to quickly transition from pre-clinical to clinical.”